In a related editorial
comment, Paolo Boffetta, M.D., M.P.H., associate director for population sciences at The Tisch Cancer Institute and chief of the Division of Cancer Prevention and Control of the at Mount Sinai in New York, addressed whether the increased risk of cancer in this group of heart failure patients
warranted additional screening beyond what was recommended for the general public.